Search | Clinical Trials Finder

Conditions: Healthy Adult Male and Female Volunteers
Interventions: ORX489 Tablets, Placebo Tablets; Drug · Other
Lead sponsor: Centessa Pharmaceuticals (UK) Limited; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 212 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Infections, Bacterial
Interventions: GSK2140944 capsule, GSK2140944 tablet, Itraconazole capsule; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Healthy Subjects
Interventions: 13 valent pneumococcal conjugate vaccine; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 15 Months to 17 Years
Enrollment: 1,200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 31
States / cities: Benton, Arkansas • Fayetteville, Arkansas • Jonesboro, Arkansas + 28 more

Conditions: Clostridium Difficile Associated Disease
Interventions: Clostridium difficile Vaccine, Placebo; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 65 Years to 85 Years
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2020
U.S. locations: 17
States / cities: DeLand, Florida • Hollywood, Florida • South Miami, Florida + 11 more

Conditions: Bacterial Infections.
Interventions: Dalbavancin; Drug
Lead sponsor: Durata Therapeutics Inc., an affiliate of Allergan plc; Industry
Eligibility: 3 Months to 11 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 10
States / cities: Little Rock, Arkansas • San Diego, California • Hartford, Connecticut + 7 more

Conditions: Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neuroblastoma, Neutropenia, Sarcoma
Interventions: voriconazole; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 2 Years to 11 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 7
States / cities: Orange, California • San Diego, California • Bethesda, Maryland + 4 more

Conditions: Myotonic Dystrophy
Interventions: SAR446268; Biological
Lead sponsor: Sanofi; Industry
Eligibility: 10 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 4
States / cities: Gainesville, Florida • Tampa, Florida • New York, New York + 1 more

Conditions: CNS
Interventions: E2006, Placebo comparator; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 2
States / cities: Culver City, California • Glendale, California

Conditions: Congenital Adrenal Hyperplasia
Interventions: Chronocort®, Standard Care; Drug
Lead sponsor: Neurocrine UK Limited; Industry
Eligibility: 16 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Morehead City, North Carolina

Conditions: Healthy, Elderly
Interventions: PF-04447943, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 65 Years to 85 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Atopic Dermatitis
Interventions: Rocatinlimab; Drug
Lead sponsor: Amgen; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 22
States / cities: Phoenix, Arizona • Tempe, Arizona • Bryant, Arkansas + 17 more

Conditions: Staphylococcal Infections
Interventions: SA4Ag vaccine, Blood sample; Biological · Procedure
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 2
States / cities: Hollywood, Florida • South Miami, Florida

Conditions: Healthy
Interventions: Ad26.RSV.preF 5*10^10 vp, Ad26.RSV.preF 1*10^11 vp, Placebo; Biological · Drug
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 60 Years and older
Enrollment: 73 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Influenza
Interventions: MF59-eH1N1_f; Biological
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 2,719 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 20
States / cities: Miami, Florida • Lenexa, Kansas • Omaha, Nebraska + 16 more

Conditions: Friedreich Ataxia
Interventions: Omaveloxolone; Drug
Lead sponsor: Biogen; Industry
Eligibility: 2 Years to 15 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Healthy, Elderly
Interventions: PF-04447943; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 65 Years to 85 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Chronic Kidney Disease, Secondary Hyperparathyroidism
Interventions: Etelcalcetide; Drug
Lead sponsor: Amgen; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 3
States / cities: Los Angeles, California • Louisville, Kentucky • Kansas City, Missouri

Conditions: Alzheimer's Disease
Interventions: TC-5619, Placebo; Drug
Lead sponsor: Targacept Inc.; Industry
Eligibility: 55 Years to 80 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 10
States / cities: Long Beach, California • San Francisco, California • Hallandale, Florida + 7 more

Conditions: Advanced Age-related Macular Degeneration
Interventions: LFG316; Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 55 Years to 90 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 8
States / cities: Phoenix, Arizona • Beverly Hills, California • Fort Myers, Florida + 5 more

Conditions: Healthy Volunteers
Interventions: E2511, Placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Glendale, California

Conditions: Healthy Participants
Interventions: BMS-986368; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Respiratory Syncytial Viruses
Interventions: Lumicitabine, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 28 Days to 36 Months
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 6
States / cities: Long Beach, California • Kansas City, Missouri • Syracuse, New York + 3 more

Conditions: Neurofibromatosis Type 1
Interventions: Selumetinib granule formulation, Selumetinib capsule formulation; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 1 Year to 6 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 4
States / cities: Akron, Ohio • Philadelphia, Pennsylvania • Houston, Texas + 1 more

Conditions: Clostridium Difficile
Interventions: C. difficile vaccine with adjuvant, placebo; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 184 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 6
States / cities: Overland Park, Kansas • Cary, North Carolina • Raleigh, North Carolina + 2 more

Search by objective public record fields.

A Study of ORX489 in Healthy Adult Participants, Aged 18 to 60 Years

Relative Bioavailability, Safety, Tolerability, Pharmacokinetics (PK) and Food Effect Study of GSK2140944 in Healthy Subjects

Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Healthy Children Aged 15 Months to 17 Years

A Study To Investigate Two 3-dose Schedules Of A Clostridium Difficile Vaccine In Healthy Adults Aged 65 to 85 Years

A Single Dose Study To Investigate The Pharmacokinetics and Safety Of Dalbavancin In Hospitalized Children Aged 3 Months to 11 Years.

Voriconazole in Preventing Fungal Infections in Children With Neutropenia After Chemotherapy

A Study to Investigate the Safety, Tolerability, and Efficacy of SAR446268, an Adeno-associated Viral Vector-mediated Gene Therapy in Participants Aged 10 to 55 Years of Age With Non-congenital Myotonic Dystrophy Type 1

2-Part Multiple Ascending Dose Study for Safety and Pharmacokinetics in Healthy and Elderly Subjects

Open-label Comparison of Chronocort® Versus Standard Glucocorticoid Replacement Therapy

A Phase I, Multiple Dose Study of PF-04447943 in Healthy Elderly Volunteers

A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

Evaluation of a Single Vaccination With a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) in Healthy Adults Aged 18 to <65 Years

A Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Vaccinations of Ad26.RSV.preF One Year Apart in Adults Aged 60 Years and Older in Stable Health

Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Non-Elderly and Elderly Adults

A Study to Find Out How BIIB141 (Omaveloxolone) is Processed in the Body and to Learn More About Its Safety in Participants With Friedreich's Ataxia Aged 2 to 15 Years Old

A Study to Evaluate Safety, Tolerability, Plasma Drug Levels, and Cognitive Response Following Multiple Doses of a Drug in Healthy Elderly Participants.

A Single-dose Study in Paediatric Patients Aged 2 to Less Than 18 Years With Secondary Hyperparathyroidism (sHPT) Receiving Haemodialysis

Multiple Ascending Dose Study of TC-5619 in Healthy Elderly Subjects and Subjects With Alzheimer's Disease

Intravitreal LFG316 in Patients With Advanced Age-related Macular Degeneration

A Study to Assess the Safety and Tolerability of E2511 in Healthy Adult and Elderly Participants

A Study to Evaluate the Safety, Tolerability, and Drug Levels of Orally Administered BMS-986368 in Healthy Participants, Healthy Elderly Participants, and Healthy Participants of Japanese Ethnicity

A Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine (JNJ-64041575) Regimens in Hospitalized Infants and Children Aged 28 Days to 36 Months Infected With Respiratory Syncytial Virus

Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥1 to <7 Years With NF1-related Symptomatic, Inoperable PN

A Study To Investigate A Clostridium Difficile Vaccine In Healthy Adults Aged 50 To 85 Years, Who Will Each Receive 3 Doses Of Vaccine.